|
[1]
|
Smyth, E.C., Nilsson, M., Grabsch, H.I., Van Grieken, N.C. and Lordick, F. (2020) Gastric Cancer. The Lancet, 396, 635-648. [Google Scholar] [CrossRef]
|
|
[2]
|
Ajani, J.A., D’Amico, T.A., Bentrem, D.J., et al. (2022) Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, National Comprehensive Cancer Network, 20, 167-192. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Chandra, R., Balachandar, N., Wang, S., et al. (2021) The Changing Face of Gastric Cancer: Epidemiologic Trends and Advances in Novel Therapies. Cancer Gene Therapy, 28, 390-399. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Xia, C., Dong, X., Li, H., et al. (2022) Cancer Statistics in China and United States, 2022: Profiles, Trends, and Determinants. Chinese Medical Journal, 135, 584-590. [Google Scholar] [CrossRef]
|
|
[6]
|
Sexton, R.E., Al Hallak, M.N., Diab, M., et al. (2020) Gastric Cancer: A Comprehensive Review of Current and Future Treatment Strategies. Cancer and Metastasis Reviews, 39, 1179-1203. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Ono, H., Yao, K., Fujishiro, M., et al. (2021) Guidelines for Endoscopic Submucosal Dissection and Endoscopic Mucosal Resection for Early Gastric Cancer (Second Edition). Digestive Endoscopy, 33, 4-20. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Song, Z., Wu, Y., Yang, J., et al. (2017) Progress in the Treatment of Advanced Gastric Cancer. Tumor Biology, 39. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Janjigian, Y.Y., Shitara, K., Moehler, M., et al. (2021) First-Line Nivolumab plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 398, 27-40. [Google Scholar] [CrossRef]
|
|
[10]
|
Liu, J., Chen, Z., Li, Y., et al. (2021) PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Frontiers in Pharmacology, 12, Article ID: 731798. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Gordon, S.R., Maute, R.L., Dulken, B.W., et al. (2017) PD-1 Expression by Tumour-Associated Macrophages Inhibits Phagocytosis and Tumour Immunity. Nature, 545, 495-499. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Shitara, K., Van Cutsem, E., Bang, Y.J., et al. (2020) Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy Alone for Patients with First-Line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncology, 6, 1571-1580. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Rowshanravan, B., Halliday, N. and Sansom, D.M. (2018) CTLA-4: A Moving Target in Immunotherapy. Blood, 131, 58-67. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Xu, X., Dennett, P., Zhang, J., et al. (2023) CTLA4 Depletes T Cell Endogenous and Trogocytosed B7 Ligands via Cis-Endocytosis. Journal of Experimental Medicine, 220, e20221391. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Pereira, M.A., Castria, T.B., Ramos, M., et al. (2021) Cytotoxic T‐Lymphocyte‐Associated Protein 4 in Gastric Cancer: Prognosis and Association with PD‐L1 Expression. Journal of Surgical Oncology, 124, 1040-1050. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Westermann-Clark, E., Ballow, M. and Walter, J.E. (2022) The New Quest in CTLA-4 Insufficiency: How to Immune Modulate Effectively? Journal of Allergy and Clinical Immunology, 149, 543-546. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Ralph, C., Elkord, E., Burt, D.J., et al. (2010) Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 16, 1662-1672. [Google Scholar] [CrossRef]
|
|
[18]
|
Evrard, C., Louvet, C., Hajbi, F.E., et al. (2021) PRODIGE 59-DURIGAST Trial: A Randomised Phase II Study Evaluating FOLFIRI Durvalumab ± Tremelimumab in Second-Line of Patients with Advanced Gastric Cancer. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 53, 420-426. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Guo, Y., Feng, Y., Fan, P., et al. (2022) Expression and Clinical Significance of KLRG1 and 2B4 on T Cells in the Peripheral Blood and Tumour of Patients with Cervical Cancer. Immunological Investigations, 51, 670-687. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Tessmer, M.S., Fugere, C., Stevenaert, F., et al. (2007) KLRG1 Binds Cadherins and Preferentially Associates with SHIP-1. International Immunology, 19, 391-400. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Herndler-Brandstetter, D., Ishigame, H., Shinnakasu, R., et al. (2018) KLRG1 Effector CD8 T Cells Lose KLRG1, Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity. Immunity, 48, 716-729.E8. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
钱恒君. 局部晚期鼻咽癌患者外周血中淋巴细胞亚群KLRG1表达及预后分析[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2022.
|
|
[23]
|
Li, L., Wan, S., Tao, K., et al. (2016) KLRG1 Restricts Memory T Cell Antitumor Immunity. Oncotarget, 7, 61670-61678. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Liu, L., You, X., Han, S., et al. (2021) CD155/TIGIT, a Novel Immune Checkpoint in Human Cancers (Review). Oncology Reports, 45, 835-845. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Yu, X., Harden, K., Gonzalez, L.C., et al. (2009) The Surface Protein TIGIT Suppresses T Cell Activation by Promoting the Generation of Mature Immunoregulatory Dendritic Cells. Nature Immunology, 10, 48-57. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Chauvin, J.M., Pagliano, O., Fourcade, J., et al. (2015) TIGIT and PD-1 Impair Tumor Antigen-Specific CD8 T Cells in Melanoma Patients. Journal of Clinical Investigation, 125, 2046-2058. [Google Scholar] [CrossRef]
|
|
[27]
|
Wolf, Y., Anderson, A.C. and Kuchroo, V.K. (2020) TIM3 Comes of Age as an Inhibitory Receptor. Nature Reviews Immunology, 20, 173-185. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Koyama, S., Akbay, E.A., Li, Y.Y., et al. (2016) Adaptive Resistance to Therapeutic PD-1 Blockade Is Associated with Upregulation of Alternative Immune Checkpoints. Nature Communications, 7, Article No. 10501.
|
|
[29]
|
Ngiow, S.F., Von Scheidt, B., Akiba, H., et al. (2011) Anti-TIM3 Antibody Promotes T Cell IFN-γ-Mediated Antitumor Immunity and Suppresses Established Tumors. Cancer Research, 71, 3540-3551. [Google Scholar] [CrossRef]
|
|
[30]
|
Cheng, G., Li, M., Wu, J., et al. (2015) Expression of Tim-3 in Gastric Cancer Tissue and Its Relationship with Prognosis. International Journal of Clinical and Experimental Pathology, 8, 9452-9457.
|
|
[31]
|
Park, Y., Seo, A.N., Koh, J., et al. (2021) Expression of the Immune Checkpoint Receptors PD-1, LAG3, and TIM3 in the Immune Context of Stage II and III Gastric Cancer by Using Single and Chromogenic Multiplex Immunohistochemistry. Oncoimmunology, 10, Article ID: 1954761. [Google Scholar] [CrossRef]
|
|
[32]
|
Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews. Cancer, 12, 252-264. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Andrews, L.P., Marciscano, A.E., Drake, C.G., et al. (2017) LAG3 (CD223) as a Cancer Immunotherapy Target. Immunological Reviews, 276, 80-96. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Li, N., Jilisihan, B., Wang, W., et al. (2018) Soluble LAG3 Acts as a Potential Prognostic Marker of Gastric Cancer and Its Positive Correlation with CD8 T Cell Frequency and Secretion of IL-12 and INF-γ in Peripheral Blood. Cancer Biomarkers: Section A of Disease Markers, 23, 341-351. [Google Scholar] [CrossRef]
|
|
[35]
|
Lv, K., Li, R., Cao, Y., et al. (2021) Lymphocyte-Activation Gene 3 Expression Associates with Poor Prognosis and Immunoevasive Contexture in Epstein-Barr Virus-Positive and MLH1-Defective Gastric Cancer Patients. International Journal of Cancer, 148, 759-768. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Raufi, A.G. and Klempner, S.J. (2015) Immunotherapy for Advanced Gastric and Esophageal Cancer: Preclinical Rationale and Ongoing Clinical Investigations. Journal of Gastrointestinal Oncology, 6, 561-569.
|
|
[37]
|
Webb, G.J., Hirschfield, G.M. and Lane, P.J.L. (2016) OX40, OX40L and Autoimmunity: A Comprehensive Review. Clinical Reviews in Allergy & Immunology, 50, 312-332. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Cebada, J., Perez-Santos, M., Bandala, C., et al. (2021) OX40 Agonists for Cancer Treatment: A Patent Review. Expert Opinion on Therapeutic Patents, 31, 81-90. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Redmond, W.L., Ruby, C.E. and Weinberg, A.D. (2009) The Role of OX40-Mediated Co-Stimulation in T-Cell Activation and Survival. Critical Reviews in Immunology, 29, 187-201. [Google Scholar] [CrossRef]
|
|
[40]
|
Dong, C., Juedes, A.E., Temann, U.A., et al. (2001) ICOS Co-Stimulatory Receptor Is Essential for T-Cell Activation and Function. Nature, 409, 97-101. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Amatore, F., Gorvel, L. and Olive, D. (2020) Role of Inducible Co-Stimulator (ICOS) in Cancer Immunotherapy. Expert Opinion on Biological Therapy, 20, 141-150. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Collin, M. (2016) Immune Checkpoint Inhibitors: A Patent Review (2010-2015). Expert Opinion on Therapeutic Patents, 26, 555-564. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Oda, S.K., Anderson, K.G., Ravikumar, P., et al. (2020) A Fas-4-1BB Fusion Protein Converts a Death to a Pro-Survival Signal and Enhances T Cell Therapy. The Journal of Experimental Medicine, 217, e20191166. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Segal, N.H., Logan, T.F., Hodi, F.S., et al. (2017) Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 23, 1929-1936. [Google Scholar] [CrossRef]
|